Proteonomix, Inc. (PROT)
PROT Stock Price Chart
Explore Proteonomix, Inc. interactive price chart. Choose custom timeframes to analyze PROT price movements and trends.
PROT Company Profile
Discover essential business fundamentals and corporate details for Proteonomix, Inc. (PROT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jul 1997
Employees
—
Website
https://www.proteonomix.comCEO
Michael Cohen
Description
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
PROT Financial Timeline
Browse a chronological timeline of Proteonomix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
PROT Stock Performance
Access detailed PROT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.